The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes. / Dahlström, Emma H.; Saksi, Jani; Forsblom, Carol; Uglebjerg, Nicoline; Mars, Nina; Thorn, Lena M.; Harjutsalo, Valma; Rossing, Peter; Ahluwalia, Tarunveer S.; Lindsberg, Perttu J.; Sandholm, Niina; Groop, Per Henrik; FinnDiane Study Group.

In: Diabetes, Vol. 70, No. 10, 2021, p. 2391-2401.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Dahlström, EH, Saksi, J, Forsblom, C, Uglebjerg, N, Mars, N, Thorn, LM, Harjutsalo, V, Rossing, P, Ahluwalia, TS, Lindsberg, PJ, Sandholm, N, Groop, PH & FinnDiane Study Group 2021, 'The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes', Diabetes, vol. 70, no. 10, pp. 2391-2401. https://doi.org/10.2337/db21-0056

APA

Dahlström, E. H., Saksi, J., Forsblom, C., Uglebjerg, N., Mars, N., Thorn, L. M., Harjutsalo, V., Rossing, P., Ahluwalia, T. S., Lindsberg, P. J., Sandholm, N., Groop, P. H., & FinnDiane Study Group (2021). The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes. Diabetes, 70(10), 2391-2401. https://doi.org/10.2337/db21-0056

Vancouver

Dahlström EH, Saksi J, Forsblom C, Uglebjerg N, Mars N, Thorn LM et al. The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes. Diabetes. 2021;70(10):2391-2401. https://doi.org/10.2337/db21-0056

Author

Dahlström, Emma H. ; Saksi, Jani ; Forsblom, Carol ; Uglebjerg, Nicoline ; Mars, Nina ; Thorn, Lena M. ; Harjutsalo, Valma ; Rossing, Peter ; Ahluwalia, Tarunveer S. ; Lindsberg, Perttu J. ; Sandholm, Niina ; Groop, Per Henrik ; FinnDiane Study Group. / The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes. In: Diabetes. 2021 ; Vol. 70, No. 10. pp. 2391-2401.

Bibtex

@article{da6a96bfc5db40108bdb63f4c409d7e5,
title = "The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes",
abstract = "Fatty acid binding protein 4 (FABP4) is implicated in the pathogenesis of cardiometabolic disorders. Pharmacological inhibition or genetic deletion of FABP4 improves cardiometabolic health and protects against atherosclerosis in preclinical models. As cardiovascular disease (CVD) is common in type 1 diabetes, we examined the role of FABP4 in the development of complications in type 1 diabetes, focusing on a functional, low-expression variant (rs77878271) in the promoter of the FABP4 gene. For this, we assessed the risk of CVD, stroke, coronary artery disease (CAD), end-stage kidney disease, and mortality using Cox proportional hazards models for the FABP4 rs77878271 in 5,077 Finnish individuals with type 1 diabetes. The low-expression G allele of rs77878271 increased the risk of CVD, independent of confounders. Findings were tested for replication in 852 Danish and 3,678 Finnish individuals with type 1 diabetes. In the meta-analysis, each G allele increased the risk of stroke by 26% (P = 0.04), CAD by 26% (P = 0.006), and CVD by 17% (P = 0.003). In Mendelian randomization, a 1-SD unit decrease in FABP4 increased risk of CAD 2.4-fold. Hence, in contrast with the general population, among patients with type 1 diabetes the low-expression G allele of rs77878271 increased CVD risk, suggesting that genetically low FABP4 levels may be detrimental in the context of type 1 diabetes.",
author = "Dahlstr{\"o}m, {Emma H.} and Jani Saksi and Carol Forsblom and Nicoline Uglebjerg and Nina Mars and Thorn, {Lena M.} and Valma Harjutsalo and Peter Rossing and Ahluwalia, {Tarunveer S.} and Lindsberg, {Perttu J.} and Niina Sandholm and Groop, {Per Henrik} and {FinnDiane Study Group}",
note = "Publisher Copyright: {\textcopyright} 2021 by the American Diabetes Association.",
year = "2021",
doi = "10.2337/db21-0056",
language = "English",
volume = "70",
pages = "2391--2401",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "10",

}

RIS

TY - JOUR

T1 - The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 Diabetes

AU - Dahlström, Emma H.

AU - Saksi, Jani

AU - Forsblom, Carol

AU - Uglebjerg, Nicoline

AU - Mars, Nina

AU - Thorn, Lena M.

AU - Harjutsalo, Valma

AU - Rossing, Peter

AU - Ahluwalia, Tarunveer S.

AU - Lindsberg, Perttu J.

AU - Sandholm, Niina

AU - Groop, Per Henrik

AU - FinnDiane Study Group

N1 - Publisher Copyright: © 2021 by the American Diabetes Association.

PY - 2021

Y1 - 2021

N2 - Fatty acid binding protein 4 (FABP4) is implicated in the pathogenesis of cardiometabolic disorders. Pharmacological inhibition or genetic deletion of FABP4 improves cardiometabolic health and protects against atherosclerosis in preclinical models. As cardiovascular disease (CVD) is common in type 1 diabetes, we examined the role of FABP4 in the development of complications in type 1 diabetes, focusing on a functional, low-expression variant (rs77878271) in the promoter of the FABP4 gene. For this, we assessed the risk of CVD, stroke, coronary artery disease (CAD), end-stage kidney disease, and mortality using Cox proportional hazards models for the FABP4 rs77878271 in 5,077 Finnish individuals with type 1 diabetes. The low-expression G allele of rs77878271 increased the risk of CVD, independent of confounders. Findings were tested for replication in 852 Danish and 3,678 Finnish individuals with type 1 diabetes. In the meta-analysis, each G allele increased the risk of stroke by 26% (P = 0.04), CAD by 26% (P = 0.006), and CVD by 17% (P = 0.003). In Mendelian randomization, a 1-SD unit decrease in FABP4 increased risk of CAD 2.4-fold. Hence, in contrast with the general population, among patients with type 1 diabetes the low-expression G allele of rs77878271 increased CVD risk, suggesting that genetically low FABP4 levels may be detrimental in the context of type 1 diabetes.

AB - Fatty acid binding protein 4 (FABP4) is implicated in the pathogenesis of cardiometabolic disorders. Pharmacological inhibition or genetic deletion of FABP4 improves cardiometabolic health and protects against atherosclerosis in preclinical models. As cardiovascular disease (CVD) is common in type 1 diabetes, we examined the role of FABP4 in the development of complications in type 1 diabetes, focusing on a functional, low-expression variant (rs77878271) in the promoter of the FABP4 gene. For this, we assessed the risk of CVD, stroke, coronary artery disease (CAD), end-stage kidney disease, and mortality using Cox proportional hazards models for the FABP4 rs77878271 in 5,077 Finnish individuals with type 1 diabetes. The low-expression G allele of rs77878271 increased the risk of CVD, independent of confounders. Findings were tested for replication in 852 Danish and 3,678 Finnish individuals with type 1 diabetes. In the meta-analysis, each G allele increased the risk of stroke by 26% (P = 0.04), CAD by 26% (P = 0.006), and CVD by 17% (P = 0.003). In Mendelian randomization, a 1-SD unit decrease in FABP4 increased risk of CAD 2.4-fold. Hence, in contrast with the general population, among patients with type 1 diabetes the low-expression G allele of rs77878271 increased CVD risk, suggesting that genetically low FABP4 levels may be detrimental in the context of type 1 diabetes.

U2 - 10.2337/db21-0056

DO - 10.2337/db21-0056

M3 - Journal article

C2 - 34244239

AN - SCOPUS:85115844778

VL - 70

SP - 2391

EP - 2401

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 10

ER -

ID: 284107017